Chen Jeng-Chang, Chang Ming-Ling, Lin Jer-Nan, Lai Hong-Shiee, Chen Chiu-Chiang, Chen Wei-Jao, Hung Wen-Tsung
Department of Surgery, Chang Gung Children's Hospital, 5 Fu-Shin Street, Kweishan, 333, Taoyuan, Taiwan, China.
World J Gastroenterol. 2005 Sep 14;11(34):5289-94. doi: 10.3748/wjg.v11.i34.5289.
To examine the differences of clinical behaviors between hepatocellular carcinomas (HCC) and hepatoblastomas (HB) in children.
From 1979 to 1997, we collected 73 HCC and 54 HB from two major medical centers in Taiwan. Demog-raphic, laboratory and radiological data, and survival curves were statistically compared.
HCC clinically differed from HB in mean age (10.6 vs 2.5 years; P<0.001), status of hepatitis B infection (56/56 vs 4/35, P<0.001) and accompanying liver cirrhosis (26/40 vs 0/30, P<0.001), portal vein thrombi (22/56 vs 5/38, P = 0.006) and para-aortic lymphadenopathy (10/56 vs 1/38, P = 0.026). Due to a higher recurrence rate (7/12 vs 2/13, P = 0.041), stage I HCC compared poorly in survivals with stage I HB (P = 0.0183). Chemotherapy could only benefit HB as evidenced by 66.7% of resectability conversion and improve survivals for advanced HB, even with unsuccessful conversion. The survival difference between stage I HB and advanced HB with delayed complete resection was of borderline insignificance (P = 0.0507).
HCC and HB were preliminarily distinguishable by some clinical clues. Delayed resection after chemotherapy was only possible for HB. However, further studies are needed to strengthen our observation that appropriate reliance upon chemotherapy to subsequently resect advanced HB could achieve the comparable survival to that of stage I HB.
探讨儿童肝细胞癌(HCC)和成肝细胞瘤(HB)临床行为的差异。
1979年至1997年,我们从台湾两个主要医疗中心收集了73例HCC和54例HB。对人口统计学、实验室和放射学数据以及生存曲线进行了统计学比较。
HCC与HB在平均年龄(10.6岁对2.5岁;P<0.001)、乙肝感染状况(56/56对4/35,P<0.001)、伴发肝硬化(26/40对0/30,P<0.001)、门静脉血栓(22/56对5/38,P = 0.006)和主动脉旁淋巴结肿大(10/56对1/38,P = 0.026)方面存在临床差异。由于复发率较高(7/12对2/13,P = 0.041),I期HCC的生存率与I期HB相比欠佳(P = 0.0183)。化疗仅对HB有益,66.7%的可切除性转化以及晚期HB生存率的提高证明了这一点,即使转化未成功。I期HB与延迟完全切除的晚期HB之间的生存差异临界无显著性(P = 0.0507)。
HCC和HB可通过一些临床线索初步区分。化疗后延迟切除仅适用于HB。然而,需要进一步研究来强化我们的观察结果,即对晚期HB适当依赖化疗随后进行切除可实现与I期HB相当的生存率。